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Objectives The aim of this study was to determine the prognostic utility of midregion proadrenomedullin (MR-proADM) in all
patients, cardiac and noncardiac, presenting with acute shortness of breath.
Background The recently published BACH (Biomarkers in Acute Heart Failure) study demonstrated that MR-proADM had su-
perior accuracy for predicting 90-day mortality compared with B-type natriuretic peptide (area under the curve:
0.674 vs. 0.606, respectively, p  0.001) in acute heart failure.
Methods The BACH trial was a prospective, 15-center, international study of 1,641 patients presenting to the emergency
department with dyspnea. Using this dataset, the prognostic accuracy of MR-proADM was evaluated in all pa-
tients enrolled for predicting 90-day mortality with respect to other biomarkers, the added value in addition to
clinical variables, as well as the added value of additional measurements during hospital admission.
Results Compared with B-type natriuretic peptide or troponin, MR-proADM was superior for predicting 90-day all-cause mortal-
ity in patients presenting with acute dyspnea (c index  0.755, p  0.0001). Furthermore, MR-proADM added signifi-
cantly to all clinical variables (all adjusted hazard ratios: 3.28), and it was also superior to all other biomarkers. MR-
proADM added significantly to the best clinical model (bootstrap-corrected c index increase: 0.775 to 0.807; adjusted
standardized hazard ratio: 2.59; 95% confidence interval: 1.91 to 3.50; p  0.0001). Within the model, MR-proADM
was the biggest contributor to the predictive performance, with a net reclassification improvement of 8.9%. Serial
evaluation of MR-proADM performed in patients admitted provided a significant added value compared with a model
with admission values only (p  0.0005). More than one-third of patients originally at high risk could be identified by
the biomarker evaluation at discharge as low-risk patients.
Conclusions MR-proADM identifies patients with high 90-day mortality and adds prognostic value to natriuretic peptides in patients
presenting with acute shortness of breath. Serial measurement of this biomarker may also prove useful for monitor-
ing, although further studies will be required. (Biomarkers in Acute Heart Failure [BACH]; NCT00537628) (J Am Coll
Cardiol 2011;58:1057–67) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.006Adrenomedullin (ADM), a vasodilatory peptide with po-
tent hypotensive effects, is expressed in many different
tissues (1). Its plasma levels are elevated in chronic heart
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of stable analytes stoichiometri-
cally related to ADM synthesis
have been developed (9–11). Di-
rected at stable midregion pro-
hormones of the biologically
active unstable fragment, mea-
surement of midregion proADM
(MR-proADM) may provide
clinically relevant prognostic in-
formation. In the recently pub-
lished BACH (Biomarkers in
Acute Heart Failure) study, the
primary prognostic endpoint was
the utility of MR-proADM
compared with that of B-type
natriuretic peptide (BNP) for 90-
day mortality in patients diag-
nosed with acute heart failure
(AHF) (12). Using optimal cutoff
values from receiver-operating char-
acteristic curve analysis, the accu-
racy to predict survival at 90 days
for MR-proADM was 73% (95%
confidence interval [CI]: 70% to
77%), while it was 62% (95% CI:
58% to 66%) for BNP (p  0.001). In multivariate Cox
roportional hazards analysis, MR-proADM, but not BNP,
arried independent prognostic value after adjusting for age,
ex, creatinine, and troponin elevation (p  0.001). The
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ADM  adrenomedullin
AHF  acute heart failure
BNP  B-type natriuretic
peptide
CI  confidence interval
CV  coefficient of
variation
ED  emergency
department
HR  hazard ratio
IQR  interquartile range
MR-proADM  midregion
proadrenomedullin
MR-proANP  midregion
pro–atrial natriuretic
peptide
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
PCT  procalcitoninManuscript received March 14, 2011; revised manuscript received June 2, 2011,
accepted June 3, 2011.purpose of this secondary analysis was to further explore the
prognostic utility of MR-proADM in all patients, cardiac
and noncardiac, presenting with acute shortness of breath,
as well as evaluating the added value on top of clinical
variables and the added value of additional measurements
during hospital admission.
Methods
The BACH trial was a prospective, 15-center international
study of 1,641 patients presenting to the emergency depart-
ment (ED) with dyspnea and has been reported in detail
elsewhere (12).
Study population. This study was approved by the insti-
tutional review boards of all participating centers, and
patients were enrolled from March 2007 to February 2008.
To be eligible, patients had to report shortness of breath as
their primary symptom upon presentation to the ED.
Patients were excluded if they were younger than 18 years of
age, were unable to provide consent, had acute ST-segment
elevation myocardial infarctions, were receiving hemodialy-
sis, or had renal failure. The study ED physicians were
blinded to the investigational marker results. Confirmation
of diagnoses and outcomes has been described in detail (12).
easurement of biomarkers. All blood samples were
collected in plastic tubes containing ethylenediamine tetra-
acetic acid, and plasma was stored at 70°C in plastic
freezer vials. Characteristics of blood collection and sam-
pling have been described (12). MR-proADM was mea-
sured using an automated sandwich chemiluminescence
immunoassay on the KRYPTOR system (B·R·A·H·M·S
AG, Hennigsdorf/Berlin, Germany), described elsewhere
(10,11). For MR-proADM, the limit of quantification was
0.23 nmol/l; the within-run imprecision (coefficient of
variation [CV]) was 1.9%, and the between-run imprecision
(CV) was 9.8%. BNP was measured with Triage 2-site
immunoassay reagents (Biosite, Inc., San Diego, California)
formatted for Beckman Coulter instrumentation (Beckman
Coulter, Inc., Brea, California). Performance in the labora-
tory included a limit of quantitation of 5.0 ng/l, within-run
imprecision (CV) of 1.5%, and total imprecision (CV) of
3.0%. All blood samples were processed by personnel
blinded from any patient data. Copeptin, midregion pro–
atrial natriuretic peptide (MR-proANP), procalcitonin
(PCT) (all on the KRYPTOR system) and N-terminal
proBNP (NT-proBNP) (Elecsys 2010 analyzer, Roche
Diagnostics, Indianapolis, Indiana) were also measured in
our central lab, while troponin was measured locally using
both troponin T and I assays.
Statistical analysis. Values are expressed as mean  SD or
as counts and percentages as appropriate. Because of the
log-normal distribution of the biomarkers, medians and
interquartile ranges (IQRs) are reported for those. Spear-
man’s rank correlation coefficient was calculated to describe
the relationship between 2 biomarkers. A 2-sided p value
0.05 was used for statistical significance.
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mortality within 90 days after presentation to the ED. For
simplicity, we used the previously identified cutoff for
MR-proADM of 1.985 nmol/l for illustrations of predictive
performance (12).
Log-transformed values of all biomarkers were evaluated
in univariate, bivariate, and multivariate Cox regression
models to evaluate the contribution of MR-proADM over
and above that of other variables. Because differences with
respect to outcome prediction between patients diagnosed
with AHF and those diagnosed as not having AHF were
negligible for all biomarkers and clinical variables, the
multivariate analysis is reported for all patients only. To test
for differences in the predictive value of MR-proADM and
other variables, we used the likelihood ratio chi-square test
for nested models to assess whether MR-proADM added
predictive value to a clinical model and vice versa. First, we
performed bivariate Cox regression models to demonstrate
that MR-proADM is independent of each of the reported
variables. Second, we determined the best clinical model by
selecting the top 9 prognostic variables in univariate analysis
among patient characteristics, physical examination, medi-
cal history, and routine laboratory variables. To account for
outcome differences with respect to the main diagnosis
(patients with AHF are more likely to die), this variable was
also included. To this multivariate model, limited to include
10 variables to have sufficient events for evaluation, MR-
proADM was added and the added value evaluated using
both nested Cox regression models and net reclassification
improvement (NRI) (13). Risk percentile cutoffs were ap-
proximately the 10th and 90th percentiles of predicted risk
on the basis of the best clinical model (predicted risk at 2%
and 19%, respectively).
For continuous variables, hazard ratios (HRs) were stan-
dardized to describe the HR for a biomarker change of 1
IQR. The predictive value of each model was assessed by
the model likelihood ratio chi-square statistic. The c index
is given as an effect measure. It is equivalent to the concept
of area under the curve adopted for binary outcomes. For
multivariate models, a bootstrap-corrected version of the c
index is given. Kaplan-Meier survival curves were plotted
using the MR-proADM cutoff.
To evaluate whether re-evaluation of the biomarker at a
later point in time provided additional prognostic informa-
tion, we applied a time-dependent Cox regression model.
Missing values were replaced using the last-observation-
carried-forward rule, and missing draw times were replaced
using the median draw times (1 day for the second mea-
surement and 7 days for the discharge value).
All statistical analyses were performed using R version
2.5.1 (R Foundation for Statistical Computing, Vienna,
Austria), SAS version 9.1 (SAS Institute Inc., Cary, North
Carolina), or SPSS version 16.0 (SPSS, Inc., Chicago,
Illinois).
The data management center and research department of
the VA San Diego Healthcare System (San Diego, Califor- Onia) was responsible for data quality control and statistical
analysis.
Results
Description of general population. A total of 1,641 pa-
tients were evaluated. Of these, the adjudicated diagnosis
was AHF in 568 patients (34.6%). Of the 1,073 remaining
patients (65.4%), final diagnoses were chronic obstructive
pulmonary disease in 201 (12.2%), asthma in 130 (7.0%),
pneumonia in 112 (6.8%), chest pain of unknown origin in
106 (6.5%), bronchitis in 61 (3.7%), arrhythmia in 55
(3.4%), acute coronary syndromes in 39 (2.4%), pulmonary
embolism in 38 (2.3%), influenza in 27 (1.6%), and “other”
diseases as a primary diagnosis in 304 (18.5%). There were
130 deaths within 90 days (survival rate 92.1%; 95% CI:
90.7% to 93.3%). Of the 568 patients with AHF, 65 died
within 90 days (90-day survival rate 88.6%; 95% CI: 85.6%
to 90.9%). Among the 1,073 patients without AHF, there
were 65 deaths within 90 days (90-day survival rate 93.9%;
95% CI: 92.3% to 95.2%).
The patient characteristics of patients alive or dead at 90
days are presented in Table 1. Patients who died were older,
more likely to be white, had lower blood pressures, had
lower body mass indexes, and were more likely to be overtly
volume overloaded, as evidenced by rales, elevated jugular
venous pressure, edema, and ascites. They were also more
likely to be on warfarin, diuretic agents, digoxin, or aldo-
sterone inhibitors (data not shown). The trend for all
differences was identical in patients with AHF and in those
without. In the non-AHF group, patients who died were
more likely to be male, had higher heart rates, were more
likely to have pacemakers or to have undergone percutane-
ous coronary intervention, and were less likely to be on
nebulizers or to use inhalers, while no significant differences
were observed for these variables in the AHF group (Online
Table 1). Causes of death as recorded were as follows:
congestive heart failure in 39 (30%), other cardiac diseases
in 10 (7.7%), chronic obstructive pulmonary disease in 12
(9.2%), sepsis in 7 (5.4%), lower respiratory tract infection
in 4 (3.1%), and other reasons not further specified in 58
(44.6%).
Descriptive analysis of biomarker measurements. Valid
measurements for MR-proADM were obtained for 99.6%
of all patient samples (6 failures among 1,641 patients). For
BNP and NT-proBNP, the rates were 99.8% (3 failures)
and 98.9% (18 failures), respectively. MR-proADM levels
ranged from 0.03 to 12.6 nmol/l, with a median of 0.88
nmol/l and an IQR of 0.57 to 1.44 nmol/l. Spearman’s
correlation coefficients between MR-proADM and BNP,
NT-proBNP, and troponin were 0.72, 0.76, and 0.32,
respectively. Table 2 shows the biomarker median values by
utcome at 90 days. All biomarkers were significantly higher
n patients who died during follow-up (p  0.002) (see alsonline Fig. 1).
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Variable n Dead (n  130) Alive (n  1,511) p Value
Demographics
Age (yrs) 1,641 72.8 13.2 63 17 0.0001
Male 1,641 79 (60.8%) 780 (51.6%) 0.0543
Race 1,626 0.0005
White 976 (65.2%) 114 (88.4%)
Black 462 (30.9%) 14 (10.9%)
Other 59 (3.9%) 1 (0.8%)
Recent history
Smoking 1593 32 (26.9%) 437 (29.6%) 0.6013
Wheezing 1,543 26 (22.6%) 442 (31%) 0.0725
Weight gain 1,438 24 (22.9%) 225 (16.9%) 0.1394
Night sweats 1,495 26 (23.2%) 298 (21.5%) 0.7205
Orthopnea 1,536 67 (55.8%) 622 (43.9%) 0.0129
Dyspnea at rest 1,605 76 (59.8%) 719 (48.6%) 0.0162
Examination variables
Heart rate (beats/min) 1,641 94.4 23.3 91.2 22.8 0.1344
Systolic BP (mm Hg) 1,641 129.2 28.8 141.8 28.4 0.0001
Diastolic BP (mm Hg) 1,641 76.3 17.8 81.2 17.2 0.0031
BMI (kg/m2) 1,399 24.9 6.0 29.5 8.9 0.0001
Rales 1,624 68 (53.1%) 456 (30.5%) 0.0001
S3 1,580 5 (4%) 39 (2.7%) 0.3887
Murmur 1,604 33 (26.2%) 221 (15%) 0.0020
Elevated JVP 1,539 40 (33.9%) 231 (16.3%) 0.0001
Edema 1,615 69 (54.3%) 519 (34.9%) 0.0001
Ascites 1,579 8 (6.5%) 33 (2.3%) 0.0115
Pulse oximetry (%) 1,609 92.3 8.4 95.4 4.9 0.0001
Wheezing 1,619 30 (23.8%) 422 (28.3%) 0.3029
History variables
Arrhythmia 1,555 42 (35.6%) 363 (25.3%) 0.0164
Asthma 1,594 8 (6.4%) 310 (21.1%) 0.0001
CRI 1,584 41 (33.1%) 205 (14%) 0.0001
HF 1,597 60 (49.2%) 509 (34.5%) 0.0016
CAD 1,587 49 (40.2%) 454 (31%) 0.0425
COPD 1,594 42 (33.6%) 429 (29.2%) 0.3080
DM 1,621 38 (30.2%) 424 (28.4%) 0.6815
Hyperlipidemia 1,549 40 (34.5%) 530 (37%) 0.6181
Hypertension 1,614 90 (71.4%) 990 (66.5%) 0.2794
MI 1,584 29 (23.6%) 271 (18.5%) 0.1870
Pulmonary embolism 1,604 9 (7.2%) 76 (5.1%) 0.2998
CABG 1,615 13 (10.3%) 145 (9.7%) 0.7570
Angioplasty/stent 1,602 17 (13.7%) 187 (12.7%) 0.6763
Stroke/CVA 1,608 23 (18.1%) 142 (9.6%) 0.0054
Pacemaker/ICD 1,616 14 (11%) 148 (9.9%) 0.6460
Prosthetic valve 1,612 7 (5.6%) 36 (2.4%) 0.0742
Routine laboratory values
Sodium (mmol/l) 1,512 136.4 4.9 138.6 4.3 0.0001
Potassium (mmol/l) 1,513 4.3 0.9 4.1 0.7 0.0258
Creatinine (mg/dl) 1,514 1.6 1.1 1.3 1.2 0.0015
WBCs (per nl) 1,519 11.2 8.1 9.6 8.5 0.0364
Hemoglobin (g/dl) 1,520 12.1 2.2 12.9 2.2 0.0001
Hematocrit (%) 1,517 36.8 7.8 38.7 6.7 0.0084
Platelets (per 109 l) 1,508 243.9 114.8 256.8 109.2 0.2232
Values are mean  SD or n (%).
BMI  body mass index; BP  blood pressure; CABG  coronary artery bypass grafting; CAD  coronary artery disease; COPD  chronic obstructivepulmonary disease; CRI  chronic renal insufficiency; CVA  cardiovascular accident; DM  diabetes mellitus; HF  heart failure; ICD  implantable
cardioverter-defibrillator; JVP  jugular venous pressure; MImyocardial infarction; S3  third heart sound; WBC  white blood cell.
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without AHF. In patients without AHF, all-cause mortal-
ity at 90 days was best predicted by MR-proADM (chi-
square  89.8, c index  0.788, p  0.00001), followed by
copeptin (chi-square  66.5, c index  0.736, p 
0.00001), NT-proBNP (chi-square  59.8, c index 
0.745, p  0.00001), MR-proANP (chi-square  51.5,
c index  0.717, p  0.00001), BNP (chi-square  47.0,
c index  0.724, p  0.00001), PCT (chi-square  46.9,
c index  0.735, p  0.00001), and troponin T or I
(quantile transformed; chi-square  11.7, c index  0.646,
p  0.00064). In terms of c index, all markers performed
slightly better than for patients with AHF (12). How-
ever, the ranking of the biomarkers remained unchanged,
confirming the trend that outcome prediction is indepen-
dent of the main diagnosis observed for the clinical
variables (Online Tables 2 and 3).
Prediction of all-cause mortality within 90 days in all
patients. In all patients with acute dyspnea, all-cause mor-
tality at 90 days was also best predicted by MR-proADM
(chi-square  129.7, c index  0.755, p  0.00001),
followed by copeptin (chi-square  96.6, c index  0.727,
p  0.00001), NT-proBNP (chi-square  83.8, c index 
0.721, p  0.00001), MR-proANP (chi-square  77.7,
c index  0.705, p  0.00001), BNP (chi-square  60.1,
c index  0.691, p  0.00001), PCT (chi-square  55.5,
c index  0.704, p  0.00001), and troponin T or I
(quantile transformed; chi-square  28.7, c index  0.655,
p  0.00001).
Compared with clinical variables and routine lab vari-
ables, MR-proADM was the strongest predictor (chi-
square  129.7), followed by age (chi-square  45.5), body
mass index (chi-square  37.0), rales on examination
(chi-square  26.3), history of chronic renal insufficiency
(chi-square  25.6), sodium concentration (chi-square 
25.5), systolic blood pressure (chi-square  25.4), pulse
oximetry (chi-square  25.3), elevated jugular venous pres-
sure on examination (chi-square 20.2), and history of asthma
(chi-square 19.7) (the top 9 variables; all p values0.0001). In
bivariate Cox regression models, MR-proADM added sig-
Biomarker Values Based on 90-Day OutcomesTable 2 Biomarker Values Based on 90-Day
Biomarker n A
MR-proADM (nmol/l) 1,635
Copeptin (pmol/l) 1,627 1
NT-proBNP (pg/ml) 1,623 70
MR-proANP (pmol/l) 1,635 15
BNP (pg/ml) 1,638
PCT (ng/ml) 1,631 0
Troponin T or I (quantile transformed) 1,162 0
Troponin T (mg/l) 408 0
Troponin I (mg/l) 761 0
Values are median (interquartile range).
BNP  B-type natriuretic peptide; MR-proADM midregion proadreno
N-terminal pro–B-type natriuretic peptide; PCT procalcitonin.nificantly to all clinical variables (added chi-square 91.5for all, p  0.00001), and the adjusted HR ranged from
3.28 to 3.79. MR-proADM was also superior to all other
biomarkers; it significantly added to each of the other
biomarkers (added chi-square  41.9 for all, p  0.00001).
In contrast, of the new biomarkers, only copeptin (added
chi-square 9.2, p 0.0024) and PCT (added chi-square
4.8, p 0.0292) provided additional prognostic information
beyond MR-proADM.
Multivariate prediction of all-cause mortality within 90 days.
From the set of clinical and routine lab variables, we
determined the best clinical model for outcome prediction
by selecting the top 9 univariate variables (as listed previ-
ously) and adding the main diagnosis (AHF). MR-
proADM added significantly to this model (added chi-
square  33.7; bootstrap-corrected c index increase: 0.775
to 0.807; adjusted standardized HR: 2.59; 95% CI: 1.91 to
3.50; p  0.0001). Within the model, MR-proADM was
the biggest contributor to the predictive performance (chi-
square  38.2, p  0.0001), followed by body mass index
(chi-square  19.1, p  0.0001) and sodium (chi-square 
10.9, p  0.0010), while all other variables did not reach
significance (Table 3).
Table 4 illustrates the NRI for adding MR-proADM to
the best clinical model. Net reclassification for deaths placed
7 patients (7.9%) in higher risk categories (i.e., 12 were
pushed to higher risk, and 5 were pushed to lower risk),
while at the same time, 93 of the survivors (9.0%) ended up
in lower risk categories (i.e., 140 were pushed to lower risk,
and 47 were pushed to higher risk) (Table 4). The overall
NRI using risk categories of 2%, 2% to 19%, and 19%
is 100 of all patients (8.9%). The overall NRI for BNP was
3.9%, and that for NT-proBNP was 7.4%. Figure 1 illustrates
the prognostic performance for MR-proADM in all pa-
tients (Kaplan-Meier plot for MR-proADM deciles), as
well as performance on the basis of an optimal cut point in
patients with AHF and in those without AHF separately.
Figure 2 depicts Kaplan-Meier survival curves illustrating
the superiority of MR-proADM over BNP and NT-
proBNP. Receiver-operating characteristic–optimized cut-
offs were used for all markers (optimization on the basis of
omes
n  1,511) Dead (n  130) p Value
.6–1.4) 1.6 (1.0–3.2) 0.0001
.2–28.8) 45.0 (13.6–98.4) 0.0001
8.1–3,606.0) 5,037 (812.2–14,776.0) 0.0001
3.2–342.2) 438.9 (174–755.4) 0.0001
2–526) 525 (174–1436) 0.0001
.05–0.12) 0.16 (0.08–0.31) 0.0001
.29–0.72) 0.74 (0.39–0.90) 0.0001
.01–0.03) 0.04 (0.01–0.10) 0.0001
.02–0.06) 0.06 (0.03–0.18) 0.0011
in; MR-proANP midregion pro–atrial natriuretic peptide; NT-proBNP Outc
live (
0.8 (0
1.6 (5
4.9 (9
9.8 (6
140 (3
.07 (0
.40 (0
.01 (0
.04 (0patients diagnosed with AHF only [12]).
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provides superior and independent prognostic information
to all other available data in patients with or without heart
failure.
Prediction of all-cause mortality by diagnostic group.
Figure 3 shows the percent of patients who died during
follow-up for each gold-standard diagnostic group on the
basis of MR-proADM concentration higher or lower than
1.985 nmol/l. Across the spectrum of diagnoses, (cardiac
and noncardiac) patients with MR-proADM values higher
than 1.985 nmol/l had a significantly higher mortality rate.
Treatment monitoring using MR-proADM: value of
serial measurements. Of the 1,641 patients enrolled, 532
(32.4%) were discharged on the same day. Of the remaining
1,109 patients, 981 had at least 1 additional blood draw
within 14 to 48 h after presentation and/or at discharge.
The median time to discharge was 7 days (IQR: 3 to 12
days). Of the 981 patients included in our analysis, 120
(12.2%) died within 90 days after admission, and 40 (4.1%)
died while in the hospital.
Including all 3 serial measurements into the time-
dependent Cox model gave added value compared with the
model with the admission values only (added chi-square 
15.2, added degrees of freedom [df] 2, p 0.0005). Both
Multivariate Prediction of All-Cause MortalityTable 3 Multivariate Prediction of All-Cause Mortality
Best Clinical Model Including M
Variable Wald Chi-Square df p Value Wald Chi-Square
MR-proADM (log10, pmol/l) — — — 38.2
BNP (log10, pg/ml) — — — —
NT-proBNP (pg/ml) — — — —
BMI (kg/m2) 14.3 1 0.0002 19.1
Sodium (mmol/l) 22.7 1 0.0001 10.9
Systolic BP (mm Hg) 10.4 1 0.0012 2.4
Pulse oximetry (%) 8.5 1 0.0035 2.1
JVP on examination (yes) 2.4 1 0.1196 1.6
Age (yrs) 5.0 1 0.0259 1.3
History of asthma (yes) 1.6 1 0.2073 0.6
Diagnosis of AHF (yes) 0 1 0.8658 0.6
History of CRI (yes) 4.9 1 0.0265 0.2
Rales on examination (yes) 0.3 1 0.5751 0
AHF  acute heart failure; df  degrees of freedom; other abbreviations as in Tables 1 and 2.
Net Reclassification Index for Adding MR-proADM to the Best ClinTable 4 Net Reclassification Index for Adding MR-proADM to t
Best Clinical Model Add MR-proADM (log10, nmol/l)
Events (0, 0.02) (0.02, 0.19) (0.19, 1.00)
(0, 0.02) 2 0 0
(0.02, 0.19) 0 42 12
(0.19, 1.00) 0 5 28
Nonevents (0, 0.02) (0.02, 0.19) (0.19, 1.00)
(0, 0.02) 231 23 0
(0.02, 0.19) 107 571 24
(0.19, 1.00) 0 33 47MR-proADM  midregion proadrenomedullin.bivariate models showed added value (admission plus sec-
ond measurement 14 to 48 h later: added chi-square  4.8,
added df  1, p  0.0285; admission plus discharge
measurement: added chi-square  15.2, added df  1, p 
0.0001). Once discharge values were combined with admission
values, the second measurement no longer added prognostic
utility (added chi-square  0, added df  1, p  1.00).
To illustrate these findings, we grouped all patients
into 1 of 4 cohorts: MR-proADM high (1.985 nmol/l)
at admission and remaining high at discharge (group A,
high/high), MR-proADM high at admission but lower
than 1.985 nmol/l at discharge (group B, high/low),
MR-proADM low at admission and remaining low at
discharge (group C, low/low), and MR-proADM low at
admission but higher than 1.985 nmol/l at discharge
(group D, low/high). Patients who died before discharge
were grouped as if they would have remained in their risk
categories at admission (i.e., they were grouped as either
high/high if high at admission or low/low if low at
admission). Figure 4 illustrates the added value of a
second MR-proADM measurement at discharge. At
admission, a total of 191 patients (19.5%) had increased
MR-proADM concentrations. Of those, 70 (36.6%)
DM Including BNP and MR-proADM
Including NT-proBNP and
MR-proADM
p Value Wald Chi-Square df p Value Wald Chi-Square df p Value
0.0001 24.3 1 0.0001 18.3 1 0.0001
— 0.7 1 0.3955 — — —
— — — — 0.5 1 0.4797
0.0001 18.2 1 0.0001 17.7 1 0.0001
0.0010 11.1 1 0.0009 10.4 1 0.0013
0.1229 2.5 1 0.1110 2.5 1 0.1133
0.1435 2.3 1 0.1259 2.3 1 0.1319
0.2118 1.5 1 0.2157 1.5 1 0.2203
0.2638 1.1 1 0.2988 0.9 1 0.3515
0.4223 0.6 1 0.4281 0.6 1 0.4336
0.4550 1.2 1 0.2751 0.9 1 0.3473
0.6514 0.2 1 0.6256 0.2 1 0.6726
0.9992 0 1 0.9814 0 1 0.9965
odelst Clinical Model
-proADM (log10, nmol/l) Add Best Clinical Model
Events (0, 0.02) (0.02, 0.19) (0.19, 1.00)
(0, 0.02) 0 1 0
(0.02, 0.19) 2 34 18
(0.19, 1.00) 0 2 32
Nonevents (0, 0.02) (0.02, 0.19) (0.19, 1.00)
(0, 0.02) 102 35 0
(0.02, 0.19) 231 535 47
(0.19, 1.00) 5 32 49R-proA
df
1
—
—
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1
1
1
1
1
1
1
1
1ical Mhe Be
MR
1063JACC Vol. 58, No. 10, 2011 Maisel et al.
August 30, 2011:1057–67 Midregion-proANP in Acute DyspneaP
ro
po
rt
io
n 
of
 p
at
ie
nt
s 
su
rv
iv
in
g
Time (days)
60 %
65 %
70 %
75 %
80 %
85 %
90 %
95 %
100 %
0 20 40 60 80
MR−proADM (0.03,0.412), n=164, events=1
MR−proADM (0.412,0.519), n=163, events=2
MR−proADM (0.519,0.629), n=164, events=2
MR−proADM (0.629,0.749), n=163, events=10
MR−proADM (0.749,0.875), n=164, events=10
MR−proADM (0.875,1.06), n=163, events=9
MR−proADM (1.06,1.29), n=164, events=14
MR−proADM (1.29,1.63), n=163, events=19
MR−proADM (1.63,2.26), n=163, events=12
MR−proADM (2.26,12.6), n=164, events=50
A
B
AHF, MR−proADM<1.985 nmol/l, n=411, deaths=30
AHF, MR−proADM>1.985 nmol/l, n=153, deaths=34
Non−AHF, MR−proADM<1.985 nmol/l, n=1004, deaths=44
Non−AHF, MR−proADM>1.985 nmol/l, n=67, deaths=21
P
ro
po
rt
io
n 
of
 p
at
ie
nt
s 
su
rv
iv
in
g
Time (days)
60 %
65 %
70 %
75 %
80 %
85 %
90 %
95 %
100 %
0 20 40 60 80
HR 3.4 (2.1−5.5)
HR 8.6 (5.1−14.5)
Figure 1 Kaplan-Meier Survival Curves
(A) Kaplan-Meier survival curves on the basis of deciles of midregion proadrenomedullin (MR-proADM) for all patients with dyspnea (n  1,635). Patients with
MR-proADM concentrations within the normal range or slightly higher (first 3 deciles) had very good 90-day prognoses (survival rates ranging from 98.8% to 99.4%),
whereas those with elevated (deciles 4 to 9; survival rates ranging from 88.3% to 94.5%) or highly elevated (highest decile; survival rate 69.5%; 95% confidence interval:
61.8% to 75.9%) concentrations did considerably worse. Ranges of MR-proADM concentrations for each decile (nanomoles per liter) are shown in brackets. (B) Kaplan-
Meier survival curves on the basis of a receiver-operating characteristic–optimized cutoff of 1.985 nmol/l for MR-proADM (optimization based on patients diagnosed with
acute heart failure [AHF] only) for patients with and without AHF diagnoses. HR  hazard ratio.
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charge as low-risk patients.
Note that Figure 4 is based on combined information
rom admission and discharge, and conclusions regarding
he prognostic value of the discharge measurement alone
ay not be drawn, because a significant portion of deaths
n  40) occurred in the hospital.
iscussion
his international trial, the largest of its kind to date,
emonstrates that MR-proADM has significant prognostic
tility in patients presenting with acute shortness of breath
o the ED. We determined that MR-proADM was superior
o BNP and NT-proBNP for predicting 90-day mortality in
atients with dyspnea due to AHF (12). This was especially
rue during the first 30 days after baseline evaluation, for
hich MR-proADM clearly outperformed BNP and NT-
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Figure 2 Kaplan-Meier Survival Curves Illustrating the Superior
Receiver-operating characteristic–optimized cutoff used for B-type natriuretic pepti
patients diagnosed with acute heart failure [AHF] only) for patients diagnosed with
1.985 nmol/l, patients remain at low risk for dying within 90 days, irrespective of
MR-proADM levels higher than 1.985 nmol/l, BNP higher than 1,021 pg/ml or NT-roBNP (W. F. Peacock, unpublished data). Troponin, iecently shown to carry prognostic value in patients with
eart failure (14), was also added to a multivariate model
ith the other 3 markers. In this model, MR-proADM still
emained a strong independent prognostic factor. In the 568
ACH patients with confirmed diagnoses of AHF (35
eaths within 30 days, 65 deaths within 90 days), the
rognostic accuracy (area under the curve) of MR-proADM
evels assessed in blood samples taken on admission to the
D was 0.739 and 0.674 for 30- and 90-day follow-up,
espectively. This was greater than for both BNP (0.555 and
.606, respectively) and NT-proBNP (0.641 and 0.664,
espectively).
The present study extends these findings in a number
f important ways. First and foremost, this marker
ppears to be robust across the entire spectrum of patients
ith dyspnea. MR-proADM added significantly to all
linical models and was better than any biomarker stud-
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adding MR-proADM to the best clinical model. There-
fore, those who use natriuretic peptides to risk stratify
patients, either in the ED or the hospital, may gain
significant benefit by also measuring MR-proADM. In
patients without AHF, especially those with chronic
obstructive pulmonary disease, pneumonia, and pulmo-
nary embolism, MR-proADM was a superb predictor of
90-day mortality. These findings complement the prog-
nostic utility of MR-proADM in a number of other
settings (e.g., patients with acute myocardial infarction
[15] or non–ST-segment elevation myocardial infarction
[16], lower respiratory tract infections [17], or community-
acquired pneumonia [18]).
Both natriuretic peptides (BNP, NT-proBNP, and MR-
proANP) and troponin were mainly introduced and are
applied for diagnostic purposes: natriuretic peptides for the
diagnosis of AHF and troponin for the diagnosis of acute
myocardial infarction. Although MR-proADM proves to
add information that neither the natriuretic peptides nor
troponin (or anything else we evaluated) provided, it cannot
replace the other biomarkers for their diagnostic purposes.
Better prognostic markers may help patients in multiple
ways, as they identify those patients who should “move to
the front of the line” with respect to immediate therapeutic
interventions. In the emergency setting, untreated AHF
worsens rapidly and can lead to respiratory compromise,
intubation with mechanical ventilation, and even death.
Thus, interventions worth exploring based on high MR-
Figure 3 Percent of Patients Who Died During Follow-Up for Ea
and Dependent on MR-proADM Concentration Higher
For the primary diagnostic subgroups of asthma, bronchitis, chest pain, and influe
deaths/number of all patients in the respective subgroup. ACS  acute coronary synd
Pulm. Emb.  pulmonary embolism.proADM levels might include specialist consultation by acardiologist, intensive care unit admission, noninvasive ven-
tilation, and so on. If acute dyspnea is of unclear etiology, a
high MR-proADM level might be a strong enough reason
for hospital and possible intensive care unit admission.
Additionally, the astute clinician may follow patients with
poor prognostic markers more closely after discharge to
prevent relapse and readmission. MR-proADM levels may
also serve as a surrogate marker in therapeutic heart failure
trials, although both of these suggestions require validation.
Interventional trials are needed to prove these hypotheses.
Our data also suggest that therapy monitoring using serial
measurements of MR-proADM may be possible. About
one-third of patients considered at high risk on the basis of
MR-proADM concentrations at admission had lower con-
centrations at discharge. Their survival rate was almost as
high as that of patients who were never at risk, on the basis
of MR-proADM. This analysis has various caveats: The
necessity to replace missing values for this specific analysis
(roughly 10% of all measurements) has potential risks to
overestimate or underestimate the potential usefulness of
serial measurements. However, it is necessary, because
missing values in serial measurements do not all occur at
random. Although 1 day after admission might be too early
for a revision of the original risk stratification, for some
patients, the changing pattern is already present in the first
24 h (data not shown).
It appears that MR-proADM, a reliable surrogate of
ADM, might be more prognostic in patients with dyspnea
than biomarkers currently used in the clinical arena. Future
old-Standard Diagnostic Group
wer Than 1.985 nmol/l
deaths were observed. Numbers above each bar denote number of
AHF  acute heart failure; MR-proADM  midregion proadrenomedullin;ch G
or Lo
nza, no
rome;studies should center on MR-proADM as a guide to
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Midregion-proANP in Acute Dyspnea August 30, 2011:1057–67Figure 4 Kaplan-Meier Survival Curves on the Basis of ROC-Optimized Cutoff for MR-proADM (1.985 nmol/l,
Optimized Cutoff for Outcome Prediction in Patients Diagnosed With AHF), for All Patients With Follow-Up Blood Draws
(A) Midregion proadrenomedullin (MR-proADM) concentration available at admission grouped 191 of all patients (19.5%) as high risk (group A; estimated survival rate
72.8% [95% confidence interval (CI): 66.7% to 79.4%] vs. 91.4% [95% CI: 89.5% to 93.4%] in low-risk group B). (B) Combined information from both MR-proADM concen-
trations on admission and at discharge grouped 70 patients (36.6%) who were originally considered high risk at admission as low risk (group B), with an estimated sur-
vival rate of 90.0% (95% CI: 83.2% to 97.3%) (only slightly lower than the survival rate of patients who remained low [group C]: 92.0% [95% CI: 90.1% to 94.0%]), while
patients remaining at high risk (group A) were now estimated with a survival probability of 62.8% (95% CI: 54.8% to 72.0%). Patients who showed increasing MR-proADM
concentrations (group D, the smallest subgroup; n  24 [2.4%]) had an estimated survival rate of 70.8% (95% CI: 54.8% to 91.6%). Patients who died before discharge
were grouped as if they would have remained in their risk categories at admission (i.e., they were grouped as either high/high if high at admission or low/low if low at
admission).
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ever, it is important to recognize that our analysis must be
viewed as a post hoc reanalysis of a previously published
study with other primary endpoints. Accordingly, the con-
clusions will need to be confirmed in a new study with
pre-specified endpoints.
Study limitations. First, the number of missing values for
the multivariate analysis has potential risks, because this
might result in a biased population. Because the replace-
ment of missing values did not change the results, we
consider this controlled. With respect to the results reported
for troponin, the fact that only measurements in a subset of
patients based on locally used assays were available may have
reduced its prognostic performance. In future studies, MR-
proADM should be compared with contemporary high-
sensitive troponins. For interventional trials, multiple cut
points may be considered for MR-proADM. Although
results from observational trial can identify patients at high
risk, for whom additional therapies may prove helpful, they
are not suitable to determine a subgroup of patients for
whom treatment could be reduced. If this is the goal of an
interventional trial, a second, lower cutoff might be intro-
duced. For the evaluation of serial measurements, absolute
or relative change to identify a clinically meaningful change
may also prove more useful than a single cutoff, which we
used for illustration. It should also be noted that biomarkers
alone may not identify all patients at risk for death,
particularly if all-cause mortality is evaluated. For example,
using the cutoff optimized in patients with AHF, 33 of the
65 patients who died within 90 days in the group with heart
failure and 44 of the 65 who died in the group without heart
failure had MR-proADM levels below this cut point. Thus,
the majority of deaths were not identified by this marker
alone. And finally, despite the size of the trial (BACH is the
largest biomarker trial in AHF to date), the number of
observed deaths within 90 days is still limited (n  130
[10%]), especially for any subgroup analysis.
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